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a  b  s  t  r  a  c  t
Recent  studies  have  indicated  the Musashi2/NUMB  pathway  as  the  key  regulator  of  differentiation  in
chronic  myeloid  leukemia;  however,  a comparison  of  both  gene  expressions  has  not yet been  made
in  myelodysplastic  syndrome  (MDS)  and  in  acute  myeloid  leukemia  (AML).  We  herein,  demonstrate  a
statistically  signiﬁcant  down-modulation  of  NUMB  expression  level  in high-risk  MDS  and  AML, compared
with  control  individuals.  MSI2  expression  was  signiﬁcantly  reduced  in  low  and  high-risk  MDS  comparedeywords:
usashi 2
UMB
yelodysplastic syndromes
cute myeloid leukemia
ifferentiation
with  normal  control  samples.  NUMB  expression  was  signiﬁcantly  lower  than  that  of  MSI2  in  both  MDS  and
AML patient  samples,  but  no  differences  in  the  expression  levels  for  either  gene  were  observed  in healthy
bone  marrow  cells.  Finally,  NUMB  expression  was  signiﬁcantly  up-regulated  during  differentiation  of
normal  and  low-risk  MDS  CD34+ cells  through  the  erythroid  lineage.  Taken  together,  results  suggest  the
involvement  of  NUMB  in  MDS  erythropoiesis;  its down-modulation  may  have  a role  in MDS  progression.
 . Introduction
Musashi2/NUMB has been proposed as a potential pathway
o explain differentiation and leukemic progression in myeloid
eukemia [1,2]. The Musashi (MSI) gene codes for an evolutionarily
onserved family of RNA-binding proteins comprising two  closely
elated proteins, MSI1 and MSI2. MSI2 is predominantly expressed
n hematopoietic stem cells, and its silencing results in reduction of
ngraftment and depletion of normal HSCs, in vivo [1,2]. Originally,
UMB was identiﬁed as the ﬁrst intrinsic molecular determinant
f cell fate in Drosophila,  and later as an inhibitor of the Notch
eceptor signaling pathway [3].  MSI  is a known repressor of NUMB
ranslation and consequently an activator of Notch signaling [1].
y exploiting mouse models of chronic myeloid leukemia (CML), it
as been shown that NUMB inhibition, resulting from high levels of
SI2, is essential for development and maintenance of CML-blastrisis [1]. Interestingly, as chronic phase CML  progresses to blast cri-
is, expression of MSI2 is up-regulated and NUMB down-regulated,
nd modulation of this pathway can inhibit disease, showing that
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the MSI2/NUMB pathway controls disease progression [2]. Simi-
lar proﬁle expressions were observed in patients, where increased
levels of MSI2 in AML  and CML-blast crisis established an inverse
correlation with NUMB expression; moreover, higher MSI2 expres-
sion correlated with the risk of relapse and risk of death. MSI2
expression was deﬁned as a new prognostic marker independent
of FAB classiﬁcation, cytogenetic risk and mutation status of FLT3
and NPM1 [1,2,4–6].
To learn more about MSI2 and NUMB in hematological malig-
nancy, we  characterized the expressions of MSI2 and NUMB in
healthy controls, and in patients with myelodysplastic syndrome
(MDS), and acute myeloid leukemia (AML). Moreover, we  checked
MSI2 and NUMB expression levels during erythroid differentiation
of MDS  progenitor cells.
2. Materials and methods
2.1. Bone marrow samples
Bone marrow samples collected from 52 patients with MDS, 35
patients with AML, and 19 healthy donors were analyzed. Patients
Open access under the Elsevier OA license.and healthy donor’s characteristics are described on Table 1. All
healthy controls and patients provided informed written consent
and the study was approved by the ethics committee of the Uni-
versity of Campinas. All patients that attended the clinic between
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Table  1
Patient and control characteristics.
Number
Controls 19
Gender
Male/Female 14/05
Age (yr), median (range) 33 (16–49)
MDS  52
Gender
Male/female 31/21
Age (yr), median (range) 67 (90–16)
FAB
RA/RARS 22/08
RAEB/RAEBt 19/03
WHO
RCUD/RCMD/RARS 04/18/08
RAEB-1/RAEB-2 9/10
AML  with myelodysplasia related changesa 03
IPSS
Low risk/Intermediate-1 15/23
Intermediate-2/High risk 08/04
Not  available 02
Number of cytopenia
0/1 9/17
2/3  15/11
Number of dysplasia
0/1 02/08
2/3 19/23
BM  aspirate blast percentage
<5% 30
≥5  and < 10% 10
≥10 and < 20% 09
≥20 and < 30% 03
Cytogenetic risk stratiﬁcation
Low risk 43
Intermediate/High risk 05/02
Not available 02
AML 35
Gender
Male/Female 18/17
Age (yr), median (range) 53 (24–93)
Cytogenetic risk stratiﬁcation
Good risk 06
t(8; 21) 02
inv(16) 02
t(15; 17) 02
Intermediate risk 17
Normal karyotype 13
−Y,  del(5q) 01
+8  03
Poor risk 06
Complex karyotype 04
−7  02
Not  available 06
BM,  bone marrow; FAB, French-American-British; RA, refractory anemia; RARS,
refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess
of  blasts; RAEBt, refractory anemia with excess of blasts in transformation;
WHO, World Health Organization; RCUD, refractory cytopenia with unilineage
dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB-1, refrac-
tory  anemia with excess blast-1; RAEB-2, refractory anemia with excess blast-2;
AML, acute myeloid leukemia; IPSS, International Prognostic Score System; INT-1,
I
2
u
s
2
l
R
p
+ntermediate-1; INT-2, Intermediate-2.
a Excluded from the WHO  classiﬁcation analysis.
005 and 2011, with conﬁrmed diagnosis of MDS  or AML  and were
ntreated at the time of sample collection were included in the
tudy.
.2. Erythroid CD34+ cell differentiationFor erythroid differentiation, bone marrow samples were col-
ected from 7 low-risk and 3 high-risk MDS  patients (FAB:
A = 6, RARS = 1, RAEB = 1, RAEBt = 2). Buffy coat preparation from
eripheral blood samples were obtained from six healthy donors.arch 36 (2012) 1300– 1303 1301
CD34+ progenitors were separated on MIDI-MACS immunoafﬁnity
columns (Miltenyi Biotec, Auburn, CA) and submitted to erythroid
differentiation [7].  CD34+ cells were plated in methylcellulose
medium containing erythropoietin (EPO), stem cell factor, and
interleukin 3, and cultured for 6 days. The resulting cells (BFU-E
and CFU-E derived colony cells and proerythroblasts) were then
transferred to alpha MEM  (Gibco BR, Carisbad, CA, USA) containing
30% Fetal Calf Serum (Sigma, St. Louis, MO, USA), 10−5 M 2-
mercaptoethanol (Sigma), 2 IU/mL EPO, 300 mg/mL  Holotransferrin
(Sigma), and 1% Bovine Serum Albumin (Calbiochem, Darmstadt,
Germany) for an additional 6 days. At days 6, 8 and 12, cells were
collected and submitted to q-PCR. On days 6 and 12, cells were also
submitted to immunophenotyping.
2.3. Quantitative polymerase chain reaction (q-PCR)
Bone marrow samples were submitted to hemolysis in isotonic
ammonium chloride solution, before RNA extraction. Q-PCR was
performed with an ABI 7500 Sequence Detector System (Applied
Biosystems, Foster City, CA, USA) with speciﬁc primers for MSI2,
NUMB, and HPRT (sequences upon request). The relative gene
expression was calculated using the equation 2−CT [8] and
the median value of control group was  used as the calibrator
(Supplementary Table 1).
2.4. Statistical analysis
For comparisons, an appropriate Student’s t-test or
Mann–Whitney test was performed. A two-tailed P < 0.05 was
considered as statistically signiﬁcant.
3. Results and discussion
NUMB expression was signiﬁcantly lower than that of MSI2 in
both high-risk MDS, according to FAB, and AML  patient samples
(P < 0.01). This same pattern of MSI2 and NUMB expression has
previously been described in the chronic phase and blast crisis
of CML  [1,2], suggesting that this proﬁle expression is involved
in the malignant disease condition, since we did not observe any
expression differences for either genes in healthy bone marrow
cells (Fig. 1).
When we  compared healthy control with MDS  and AML  for
both genes, we observed a signiﬁcant decrease of NUMB expres-
sion in high-risk MDS  (P = 0.002) and AML  (P < 0.0001); a signiﬁcant
decrease of MSI2 expression in low and high-risk MDS  groups
(P < 0.05), and a trend towards a decreased MSI2 expression in
AML  (Fig. 1). The down-regulation of both genes in MDS  and
AML  suggests their cooperation in the pathophysiology of these
diseases. Interestingly, we observed statistically down-regulated
NUMB expression in AML, when compared with low-risk MDS
(P = 0.0008); the same was not observed for MSI2. It is important
to point out that same statistical differences were observed when
MDS  patients were classiﬁed according to WHO  and IPSS (data not
shown). Previous studies have shown a correlation of MSI2 with
poor prognosis in AML  [2].  We  did not observe a signiﬁcant differ-
ence in NUMB and MSI2 expressions among AML  patients that were
stratiﬁed by cytogenetic risk. In MDS, expressions of neither gene
correlated with hemoglobin nor percentage of BM blast and did not
differ among patients that were stratiﬁed by number of cytopenias
and cytogenetic risk, which probably reﬂects the limitation of the
small cohort of our study.Using CD34 cells from healthy-donors, low-risk and high-risk
MDS  patients, we also investigated MSI2 and NUMB expression
levels during erythroid differentiation. In the healthy donor and
low-risk MDS  groups, on day 12 of cell differentiation, a signiﬁcant
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Hig. 1. Comparison of MSI2 and NUMB expressions in healthy control, low and high
ndogenous control. Low-risk (RA/RARS) and high-risk MDS  (RAEB/RAEBt) were cla
atients are indicated in the ﬁgure. Mann–Whitney test.
ncrease in NUMB levels was observed (P < 0.05), whereas MSI2 lev-
ls presented no statistical difference (Fig. 2A and B). Most of the
ells were immunophenotypically characterized by the expression
f CD71 and glycophorin A, conﬁrming differentiation through the
rythroid lineage, speciﬁcally during the mid-phase of the differen-
iation program (Fig. 2D and E). In the high-risk group, cells failed
o undergo erythroid differentiation and no statistically signiﬁ-
ant changes in the expression levels of either gene were detected
ig. 2. MSI2 and NUMB expressions, normalized by HPRT endogenous control, during 12 d
ow-risk  MDS patients (B) and 3 high-risk MDS  patients (C). (D–F) Dot plot of transferrin
orizontal lines represent medians. P value is indicated in the ﬁgure. Student’s t-test.MDS, and AML. Relative expressions of MSI2 and NUMB were normalized by HPRT
d according to FAB. Horizontal lines represent medians. P value and the number of
(Fig. 2C and F). These data corroborate previous evidence that
NUMB plays a role in primitive erythropoiesis [9,10].
MDS  pathogenesis represents a complex and multistep process
that contributes to the progression of early MDS  to advanced stage
of the disease, and to the risk of development of AML. Activation and
inactivation of numerous oncogenes and tumor suppressor genes
are included in this process [11]. NUMB has been implicated in
cancer as a tumor suppressor [3];  therefore, its down-regulation
ays of erythroid differentiation culture of CD34+ cells from 6 healthy donors (A), 7
 receptor (CD71) and glycophorin A (GPA) expressions at days 6 and 12 of culture.
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n AML, when compared to MDS, suggests its role in the progres-
ion of MDS. Further studies are necessary to determine whether
his is an independent event in the pathophysiology of MDS  and
ML  or whether this has an impact on overall survival. Based on
he literature, our present results strengthen the hypothesis that
he MSI2/NUMB pathway as potential therapeutic target in hema-
ological malignancies.
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